Appendix 4E & Annual Financial Report Year End 30 June 2026
Filed with ASX · · 68 pages · English
Summary by 6ix AI
The report indicates a significant increase in revenue from customer sales and clinical services compared to the previous year, although the company reported a larger net loss for the period. Key developments include the establishment of a national clinic network and expansion of treatment programs, which are expected to enhance future revenue streams. The report also highlights the company's strategic focus on scaling its operations and enhancing clinical service efficiency.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Emyria
- 2026 Annual General Meeting - Key Dates
- Emyria Unlocks Treatment Capacity
- Notification of cessation of securities - EMD
- Change of Registered Office and Principal Place of Business
- June 2026 Quarterly Activities Report and Appendix 4C
Later from Emyria
- Revised Securities Trading Policy
- Emyria Financial Year-end Update Webinar
- Emyria Year End Presentation for Investor Webinar
- Emyria Set to Launch First NSW Clinic
- FDA Selects EMD to Present at Psychedelic Medicines Hearing
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria